Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDOP + Rituximab in Elderly NHL
NCT00120198Phase 2Terminated
- Sponsor
- Geriatric Oncology Consortium
- Start
- Mar 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in Non-Hodgkin lymphoma (NHL), sponsored by Geriatric Oncology Consortium. Primary endpoint: Feasibility and tolerability of CDOP plus rituximab. Started Mar 2005; status: terminated.
02
Drugs
doxorubicin
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00120198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120198.